Corporate & Background
 Custom Manufacturing
 Business & Products
 Facilities & Strengths
 Ethics & Values
Corporate Governance
Social Responsibilities
Environment & Safety
IPR Compliance
 Regulatory Submissions
 Investors & Financials
 Careers
 Locations & Contact
 Media Center
 Enquiry
 Home
     Our Nutraceuticals website
      News & Events

 Divi’s Labs earns a PAT of Rs.129 crores for Q4
 Divi’s Labs earns an Income of Rs.649 crores for 9M of FY10
 Divis Labs earns an Income of Rs.445 crores in H1 of FY10
 Divi’s Labs earns an Income of Rs.218 crores in Q1
 Divi’s Labs earns a PAT of Rs.417 for the year 2008-09 And declares 1:1 bonus
 Divi’s Labs PAT for 9 months
grows by 21% to Rs.309 crores
 Divi’s Labs PAT for Q2
grows by 49% to Rs.135 crores
 Divi’s Labs PAT for Q1
grows by 45% to Rs.94 crores
 Divi’s Labs PAT for FY08
grows by 87% to Rs.348 crores
 Divi’s Labs PAT for Q3
grows by 216% to Rs.99 crores
 Divi’s Labs PAT for Q2
grows by 204% to Rs.91 crores
 Divi’s Labs PAT for Q1
grows by 153% to Rs.65 crores
 Divi’s Labs PAT for FY07
grows by 167% to Rs.186 crores
 Divi’s Labs Q3 total income
 grows by 38% to Rs.152 crores
 Divis successful US-FDA
 inspection for Unit II
 Divi’s Labs Q2 total income
 grows by 97% to Rs.165 crores.
 Divi's Labs Q1 total income
 grows by 142% at Rs.165
 crores
 Divi's Laboratories earns
a net of 70 crores on an income
of Rs.392 crores in FY06
 Divi's gets nod for pharma SEZ
 Divis Laboratories earns a
 PBT of Rs.43 Crores in
 First-Half of FY06
 Divis Laboratories earns a
 total income of Rs.68
 Crores in Q1 of FY06
 Divis Laboratories earns a
 total income of Rs.365
 Crores in FY05
 Divis Laboratories earns a
 Net of Rs.105 Crores in Q3
 Divis Laboratories earns a
 PBT of Rs.45 Crores in
 First-Half of FY05
 Divis Laboratories earns a
 Net of Rs.14 Crores in Q1

Divis understands that the business segment it operates in is heavily dependent on creativity, innovation and discovery. Accordingly, it believes that in such a business environment only organizations with transparent processes have a chance to survive and grow upwards.

IPR compliance is the only way to inspire confidence in our clients and grow. At Divis we respect other’s Intellectual Property Rights as much as we defend ours agressively.

Divi commenced its business with the objective of complying with Intellectual Property Rights (IPR’s). Since commencement of manufacturing operations, Divis has been producing generic API’s using noninfringing processes. This enables the company to easily migrate to the emerging scenario, requiring IPR compliance from January 2005 onwards.

Copyright © 2006, Divis Laboratories Ltd. All Rights Reserved     Web design london